These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12963511)

  • 1. Treatment of perimenopausal women with uterine myoma: successful use of a depot GnRH agonist leading to a natural menopause.
    Imai A; Sugiyama M; Furui T; Tamaya T
    J Obstet Gynaecol; 2003 Sep; 23(5):518-20. PubMed ID: 12963511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
    Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
    Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
    Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study.
    Cirkel U; Ochs H; Schneider HP; Mettler L; Mayer-Eichberger D; Schindler AE; Bühler K; Winkler U; Zahradnik HP; Künzig HJ
    Clin Ther; 1992; 14 Suppl A():37-50. PubMed ID: 1606593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
    Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
    Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
    Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
    Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist.
    Wen L; Tseng JY; Wang PH
    Taiwan J Obstet Gynecol; 2006 Jun; 45(2):173-5. PubMed ID: 17197363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GnRH agonists in the treatment of uterine leiomyomas.
    Bianchi S; Fedele L
    Acta Eur Fertil; 1989; 20(1):5-10. PubMed ID: 2675524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical usefulness of GnRH agonist therapy for premenopausal women with uterine leiomyoma].
    Kurose T; Hando T; Shiota A
    Nihon Sanka Fujinka Gakkai Zasshi; 1995 Jan; 47(1):35-41. PubMed ID: 7844451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients.
    Hilário SG; Bozzini N; Borsari R; Baracat EC
    Fertil Steril; 2009 Jan; 91(1):240-3. PubMed ID: 18249392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
    Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
    Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effects of menopausal replacement therapy in women with uterine myomas].
    Orsini G; Pinto V; Di Biase S; D'Altorio C; Lanzilotti G
    Minerva Ginecol; 1999 Nov; 51(11):421-5. PubMed ID: 10726441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids.
    Thomas EJ
    Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical management of fibroids.
    Sankaran S; Manyonda IT
    Best Pract Res Clin Obstet Gynaecol; 2008 Aug; 22(4):655-76. PubMed ID: 18468953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of GnRHa before uterine myomectomy: report of 20 cases].
    Yu YH; Gong SP; Wan SM
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Mar; 24(3):317-9. PubMed ID: 15041550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based approach to hormonal therapies for premenopausal women with fibroids.
    Lethaby AE; Vollenhoven BJ
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):307-31. PubMed ID: 17905660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis.
    Zhang Y; Sun L; Guo Y; Cheng J; Wang Y; Fan S; Duan H
    Obstet Gynecol Surv; 2014 Feb; 69(2):100-8. PubMed ID: 25112488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of an LH-RH agonist in the management of uterine leiomyomas: a study of 17 cases.
    George M; Lhomme C; Lefort J; Gras C; Comaru-Schally AM; Schally AV
    Int J Fertil; 1989; 34(1):19-24. PubMed ID: 2565299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
    Zeng C; Gu M; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
    Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
    Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.